| First Author | Liang Y | Year | 2022 |
| Journal | Front Endocrinol (Lausanne) | Volume | 13 |
| Pages | 891379 | PubMed ID | 36082078 |
| Mgi Jnum | J:333492 | Mgi Id | MGI:7339785 |
| Doi | 10.3389/fendo.2022.891379 | Citation | Liang Y, et al. (2022) Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass. Front Endocrinol (Lausanne) 13:891379 |
| abstractText | Objective: Roux-en-Y gastric bypass is an effective intervention for metabolic disorder. We aim to elucidate whether ghrelin contributes to weight reduction, and glycemic and lipid control after Roux-en-Y gastric bypass (RYGB). Design: Four-week-old WT and Ghrl-TSC1(-/-) mice were fed high fat diet for 12 weeks before surgery, and continued to be on the same diet for 3 weeks after surgery. Body weight, food intake, glycemic and lipid metabolism were analyzed before and after surgery. Results: Gastric and circulating ghrelin was significantly increased in mice with RYGB surgery. Hypoghrelinemia elicited by deletion of TSC1 to activate mTOR signaling in gastric X/A like cells demonstrated no effect on weight reduction, glycemic and lipid control induced by Roux-en-Y gastric bypass surgery. Conclusion: Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass. |
